Park2, Park7 and Pink1 stand out among Parkinson’s disease-specific genes downregulated by both treatments, since they are involved in biological processes characteristic of this disease, like dopamine uptake and neurotransmission, autophagy and degradation of mitochondria. This evidence concerns the gene PRKN and Parkinson disease.